SCHEMBL5734087

SCHEMBL5734087

CCCCc1ccc(-c2cccc(C=O)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.50
TRIM33 Q9UPN9 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
RARB P10826 9/20 0.47
HSD11B1 P28845 2/20 0.44
RARA P10276 2/20 0.43
RARG P13631 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
MTOR P42345 1/20 0.42
KMT2A Q03164 1/20 0.42
AKR1C2 P52895 1/20 0.41
AKR1C1 Q04828 1/20 0.41
CTSV O60911 1/20 0.41
CTSL P07711 1/20 0.41
GPR84 Q9NQS5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5735859 0.90 TRIM24 (0.53) TRIM24TRIM33CA12CA1CA2
SCHEMBL5735233 0.83 TRIM24 (0.56) TRIM24TRIM33CA12CA1CA2
SCHEMBL416529 0.83 RARB (0.56) CA1CA2RARBHSD11B1RARA
SCHEMBL3032724 0.82 HDAC4 (0.47) ALDH1A1HPGD
SCHEMBL11770226 0.79 TRIM24 (0.71) TRIM24TRIM33CA12CA1CA2
SCHEMBL5736397 0.79 RARB (0.45) RARBHSD11B1RARARARGALDH1A1
SCHEMBL8436350 0.79 HSD11B1 (0.48) RARBHSD11B1RARARARGALDH1A1
SCHEMBL16572248 0.78 RARB (0.57) RARBRARARARGALDH1A1MEN1
SCHEMBL4716336 0.78 RARB (0.57) RARBRARARARGALDH1A1MEN1
SCHEMBL27728919 0.78 CA12 (0.60) TRIM24TRIM33CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO TRIM24 1668/4885TRIM33 1693/4885CA12 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.